STEP 2 · 2021

STEP 2 — Semaglutide in T2D

Semaglutide 2.4 mg in adults with overweight/obesity AND type 2 diabetes.

Headline finding

9.6% body-weight reduction vs 3.4% placebo at 68 weeks.

Population
1,210 adults with T2D and BMI ≥27
Duration
68 weeks
Citation
Davies M et al., Lancet 2021

Summary is editorial; consult the original publication for the full methodology and statistical detail.

Get matched

Want a real recommendation?

Five minutes. Free. No pressure.

Start my consultation